Development of parkinson and Alzheimer diseases in two cases of narcolepsy-cataplexy

European Neurology

Volumn 67, Issue 1, 2012, Pages 48-50

  Economou, Nicholas Tiberio ^a   Manconi, Mauro ^a   Ghika, Joseph ^b   Raimondi, Monika ^a   Bassetti, Claudio L ^a  

^a REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^b Hopital de Sion   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; GALANTAMINE; HLA DQB1 ANTIGEN; MODAFINIL; OREXIN A; PRIMIDONE; RIVASTIGMINE; VENLAFAXINE;

AGED; ALZHEIMER DISEASE; CASE REPORT; CATAPLEXY; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HALLUCINATION; HAPLOTYPE; HUMAN; LETTER; MALE; NARCOLEPSY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; REM SLEEP;

AGED; ALZHEIMER DISEASE; HUMANS; MALE; NARCOLEPSY; PARKINSON DISEASE;

EID: 83155168282     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000334733     Document Type: Letter

References (17)

1. American Academy of Sleep Medicine: International Classification of Sleep Disorders: Diagnostic and Coding Manual, ed 2. Westchester, American Academy of Sleep Medicine, 2005.
2. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL: Parkinsonism with excessive daytime sleepiness - a narcolepsylike disorder? J Neurol 2005;252:139-145.
3. Honda M, Arai T, Fukazawa M, Honda Y, et al: Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy. Neurology 2009;73:511-517.
4. Fontana A, Gast H, Reith W, Recher M, et al: Narcolepsy: autoimmunity, effector T cell activation due to infection, or T cell independent, major histocompatibility complex class II induced neuronal loss? Brain 2010;133:1300-1311.
5. Fronczek R, Overeem S, Lee SY, Hegeman IM, et al: Hypocretin (orexin) loss in Parkinson's disease. Brain 2007;130:1577-1585.
6. Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, et al: Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev 2009;13:9-22.
7. Scammell TE, Matheson JK, Honda M, Thannickal TC, Siegel JM: Coexistence of narcolepsy and Alzheimer's disease. Neurobiol Aging, Epub ahead of print.
8. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, et al: How common are the 'common' neurologic disorders? Neurology 2009;68:326-337.
9. Hobson DE, Lang AE, Martin WR, Razmy A, et al: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
10. Micallef J, Rey M, Eusebio A, Audebert C, et al: Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009;67:333-340.
11. Boivin DB, Montplaisir J: The effects of Ldopa on excessive daytime sleepiness in narcolepsy. Neurology 1991;41:1267-1269.
12. Poryazowa R, Benninger D, Waldvogel D, Bassetti CL: Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants. Eur Neurol 2010;63:129-135.
13. Nishino S, Arrigoni J, Valtier D, Miller JD, et al: Dopamine mechanisms in canine narcolepsy. J Neurosci 1991;11:2666-2671.
14. Ponz A, Khatami R, Poryazowa R, Werth E, et al: Abnormal activity in reward brain circuits in human narcolepsy with cataplexy. Ann Neurol 2010;67:190-200.
15. Fadela J, Burk JA: Orexin/hypocretin modulation of the basal forebrain cholinergic system: role in attention. Brain Res 2010;1314:112-123.
16. Siegel JM, Nienhuis R, Gulyani S, Ouyang S, et al: Neuronal degeneration in canine narcolepsy. J Neurosci 1999;19:248-257.
17. Nieoullon A, Bentue-Ferrer D, Bordet R, Tsolaki M, et al: Importance of circadian rhytmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Curr Med Res Opin 2008;24:3357-3367.